Colorado BioScience Association’s Post

This is what the future of #ClinicalResearch looks like with National Medical Fellowships, Inc. Do you care about health disparities? Medications that work effectively? Research led by Primary Investigators who can best reach underrepresented patient populations? Then please read more! This is a free training program that equips physicians to lead clinical research in their areas of specialty. The future is bright with these doctors entering the field. #NMFDctr, #ACRP2024, #ClinicalTrials Michellene Davis, Esq.,

A need not only in clinical oncology but also in Psycho-oncology

What are you proud of in your business? Really... can you post one thing that makes you incredibly proud of what you do or how your company makes a difference? 🌟 Leadership in Oncology Education: Total Health | Oncology has firmly established itself as the largest provider of free oncology education in the U.S., with over 450 conferences held and 60,000+ learner certificates issued. This comes with a 95% satisfaction rate among participants. These metrics showcase the company’s commitment to advancing oncology education on a massive scale! 🌟 Strategic Partnerships: One of the most notable and recent collaborations is with the ESMO - European Society for Medical Oncology (ESMO). This partnership marks ESMO's first significant expansion into the U.S., allowing American oncologists to access cutting-edge information from ESMO’s annual congress without having to travel. This collaboration mirrors Total Health’s similar partnership with American Society of Clinical Oncology (ASCO), through our licensing relationship, reinforcing our company’s expertise in delivering high-quality, impactful educational experiences to U.S. healthcare teams. 🌟 Impactful Events and Conferences: Total Health continues to host events where industry leaders gather to shape the future of cancer care. These events are crucial for fostering innovation and improving patient outcomes across the healthcare continuum. Our focus on the community, the patient voice, and ensuring that there is equity at podium are just some of the ways we enhance our learners' experience. 🌟 ❤️ The Team: The thing that I am most proud of is my team. A company doesn't live or grow by itself. I am surrounded by the most amazing people, mostly young, mostly Women, and I am incredibly proud of what they do every single day. No matter what--when we are on the mountaintop, or when we are in the valley--they are what I love the most about what I get to do every day! #GratefulHeart #LeadershipInAction #OncologyEducation #CompanyCulture (Some of us at the beach in Puerto Rico after set-up for the #ASCO San Juan meeting 🏖 )

#NewsFromOurCourse Our 3rd cohort of students had two intensive days of information, interaction and discussion during the block course at the start of our CAS ETH in Digital Clinical Trials continuing education programme and short course The Power of Study Design. We put patients and their needs first before continuing with study methods, types of studies and other important factors of study design. Judith Safford, President of RheumaCura shared her impressive journey to becoming an engaged patient and explained what Patient and Public Involvement (PPI) means. Ivo Schauwecker, Managing Director of the ETH digital Trial Innovation Platform and President of EUPATI Switzerland, introduced the topic with his personal story and emphasised the importance of empowering patients, noting that patients have different levels of expertise. Education is the key. Sandra Kohlmaier (née Dischinger), PPI Lead at DKF Basel, brought her expertise from a researcher's perspective and presented a PPI case study. She explained how patient involvement changed the study design and also addressed the challenges. Conny Berlin, Executive Director Patient Experience Data Science at Novartis, explained how patient preference studies can change perspectives and help assess the benefit-risk profile of a drug, and the process of designing such studies in an industry setting. Key learnings included: 1. A change of perspective is important. 2. Involve patients as valued stakeholders in all phases of a clinical research project. 3. Patients are experts on their disease because they live with it every day. 4. Patients and stakeholders must be empowered to participate. 5. More resources are needed for PPI studies - the more you invest, the more you gain. A big thank you to our lecturers for sharing their experience and expertise, and to our students for their active participation! Stay tuned for more information and check our website: https://mas-dicr.ethz.ch/ ETH Zurich | School for Continuing Education ETH Zurich - Digital Trial Innovation Platform (dTIP) RheumaCura Departement Klinische Forschung, Universität Basel Novartis #patientinvolvement #patientpreference #clinicalresearch

This is optimal.

An important step forward in the effort to narrow gaps in health care access and outcomes for ALL individuals.

"The University of California Biomedical Research Acceleration, Integration & Development (UC BRAID), in collaboration with UC Health’s Center for Data-driven Insights and Innovation (CDI2), recently partnered to offer study teams the opportunity to pioneer the use of CDI2’s UC Health Data Warehouse. Now, study teams can identify and recruit patients across the UC Health system to better meet enrollment goals and enable the recruitment of more diverse study populations. This means that researchers will be able to attract participants from different geographic locations, socio-economic statuses, and racial and ethnic backgrounds from across the state, thereby facilitating research that can better serve California's diverse communities." https://lnkd.in/gT5SBZ_i

Yes! Our LEO Foundation Center’s strategic review has been approved.   Professor Martin Malmsten, Research Director and Principal Investigator of LEO Foundation Center for Cutaneous Drug Delivery (LFCCDD), says: “This favourable and constructive review reassures us that the center is doing well and has great potential for further development. As a leader, I am both pleased and very proud.”   LFCCDD https://lnkd.in/ejJjTR6y at Department of Pharmacy, University of Copenhagen was subject to a strategic review in November by an international panel of experts, resulting in a report that recently was discussed and now approved by the LEO Foundation // LEO Fondet.   👨🔬 👩🔬 The panel was: Chair Professor Calum Drummond AO from RMIT University, Professor Marjana Tomic-Canic, University of Miami, Professor Ryan Donnelly, Queen's University Belfast and Associate Professor Pankaj Karande from Rensselaer Polytechnic Institute. They spent two days in Copenhagen where they met the center staff, Head of Department Jukka Rantanen and LEO Foundation // LEO Fondet representatives. Thank you all for two intensive days. So, what’s the short version of the panel’s report? Check it out: 1️⃣ 👉🏼 Key strengths of LFCCDD Overall, the panel is very happy with the development of the center and notes an excellent track record regarding publications and external funding. It also highlights the cohesive center construction, exemplary leadership, good mentoring, an enabling culture, and committed staff, and that individual projects share a common tread, enabling joint themes.   2️⃣ 👉🏼 LFCCDD opportunities Furthermore, the panel notes the proximity to the large-scale facilities MAX IV Laboratory and European Spallation Source ERIC as a competitive advantage for the center. Based on these considerations, the panel sees opportunities for the center to intensity its international ambitions regarding both funding and collaborations, as well as to further develop translational activities and the position of the center within the Faculty of Health and Medical Sciences, UCPH at the University of Copenhagen.   3️⃣ 👉🏼 Recommendations for future development of LFCCDD In addition, the panel recommends some aspects to be considered in the continued development of the center, including the teaching load of center staff, laboratory space, and strategies for future funding of the center. #pharmacy #skindiseases #skinresearch #dkforsk #kbhuni

The ImageBloom team is excited to announce our latest partnership with GLSA | Global Life Sciences Alliance. Find out how our collaboration aims to foster innovation and efficiency in the life sciences industry. #partnership #lifesciences #clinicaltrials #research #patientrecruitment #collaboration #imagebloom #glsa

INNOVATE® Georgia is proud to showcase #UCB in our celebration of innovation and entrepreneurship! 🚀 At UCB, we're not just a company; we're a commitment to patient value and human-centric healthcare. Our relentless focus on creating value for people living with severe diseases drives our daily endeavors. 💪 🌍 Key Insights: Patient Value Strategy: Our culture of care revolves around people's individual experiences, transforming how we do business. Digital Innovation: Leveraging AI and digital strategies to advance patient care and foster a more connected, patient-centric healthcare ecosystem. Data-Driven Decisions: We use digital capabilities to make data-driven decisions, correlating data for actionable insights and uncovering unmet needs. 💡 Patient-Centric Innovation: We prioritize patients' needs and preferences by actively engaging with them throughout our processes. Our commitment extends beyond medicines, aiming to create a more patient-centric healthcare experience. 👥 Diverse Talents: Our diverse team of approximately 8,600 employees across nearly 40 countries empowers our digital commitment. With unique strengths and talents, we invest in cutting-edge scientific research to meet unmet patient needs. 🌿 Sustainability Efforts: Beyond our groundbreaking scientific work, UCB is committed to green sustainability and community giving. Our Atlanta campus, "The Warehouse," achieved LEED Gold and WELL Platinum certifications, a testament to our commitment to sustainability. 👩🔬 Community Impact: Our community giving focuses on STEM education, contributing to six local STEM organizations in Atlanta, Boston, and Seattle in 2022. We aim to inspire and build a stronger workforce for the future of the biopharma industry. ⚡ Digital Transformation: Empowering a digital-first mindset, we embrace continuous learning and adaptability. Our digitally-versed teams use data and technology purposefully, correlating insights to improve patient value. 🔗 Read More About UCB's Innovation Journey: https://lnkd.in/dqEJGXR5 Join us in celebrating UCB's commitment to innovation, patient value, and a healthier future! 🎊 Feel free to share your thoughts and be part of the conversation. 🚀 #InnovationSpotlight #HealthcareInnovation #UCBInnovates Glen Edwards Susan Ritzheimer UCB